Our study suggested that TP53 mutation tended to confer poor survival and potential negative predictive effect associated with a non-response to platinum-based chemotherapy and erlotinib in early-stage EGFR-mutated resected NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.